C3991041

The Pfizer Clinical Research Unit in New Haven is seeking healthy volunteers for a clinical trial of a study drug for type 2 diabetes and general weight management and blood sugar control. This study will look at the effects of the study drug when taken with two other medications.

Type 2 diabetes (T2D) is a chronic disease that occurs when a person’s body does not make or use insulin effectively to regulate blood sugar. Despite the availability of multiple treatments, approximately half of people diagnosed with T2D are not at their blood sugar goal.

Harnessing our legacy and expertise in cardiovascular and metabolic diseases, Pfizer aims to identify and develop breakthrough treatments for people with this disease.

Read more about this study below and see how you can make a difference as a healthy volunteer.

Card Summary Component

Who may participate

By volunteering in clinical research, you can make a difference for patients.

This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements: 

  • Willing to take a study drug
  • Willing and able to come to our facility in New Haven, CT*
  • Able to fast for up to 12 hours
  • Current BMI >25

*participants may be eligible to receive a bonus for travel, ask our staff for details

There are other requirements for participation in this study. The study staff will explain these to you during the screening process.

 

Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus. 

Learn more
Condition

Healthy

Age

18+ years

Sex

All sexes

Referral bonus

Up to $150

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.

If you choose to participate,, you will stay at our facility for 20 overnights. Starting the morning after admission, you will receive the following study interventions in order:

  • A single dose of the study drug
  • A single dose of the study drug combined with a single oral dose of another medication
  • A once-daily dose of an additional medication for 9 days, plus a single oral dose of the study drug on the 4th day

There are about 5 days between each intervention. All doses are given after a morning meal and may be provided in the form of tablets, capsules, or a liquid solution to swallow.

Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.

Download consent form
Required overnight stays

20

Long-term follow up

1 phone call

How long is this study?

About 49 days

Compensation

Up to $6,820 upon completion of the study*

All of the study procedures will be clearly explained to you during screening and can be viewed by downloading the informed consent form.

Interested in participating?

Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you. Please note: volunteers completing this form must be able to read and speak English at an 8th grade level.

You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.

For Japanese language assistance only, please call 1-833-711-9984. We apologize, our representatives cannot take calls in languages other than English or Japanese at this time.

The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.

Cancel